The Filing Desk

Eton Pharmaceuticals

ETON · Nasdaq · Health Care · Financials, fiscal 2018 to 2025

ETON · Last close · November 13, 2026
$63.93
Value Eton Pharmaceuticals yourself

Eton Pharmaceuticals' revenue rose 104.9% to $80 million in fiscal 2025. Its operating margin was −1.1%, up from −6.7% a year earlier. Free cash flow was $10 million, up 980.7%. The diluted share count rose 3.9%.

ETON PHARMACEUTICALS, INC. Latest fiscal year ended December 31, 2025 10-K filed March 19, 2026 · 0001437749-26-009059 Updated
Revenue
$80M
104.9%
Operating margin
−1.1%
5.6 pts
Net income
−$5M
 
Free cash flow
$10M
980.7%
Return on capital
−1.9%
10.4 pts
Market cap
$2.1B
Nov 13 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Eton Pharmaceuticals does

Eton Pharmaceuticals develops and sells treatments for rare diseases. It has eight products on the market, including INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN and PKU GOLIKE, and five more candidates in late-stage development.

It earns revenue from selling these products, mostly in the United States. INCRELEX treats children with severe primary insulin-like growth factor 1 deficiency, and Eton bought and launched it in December 2024. ALKINDI SPRINKLE and KHINDIVI are hydrocortisone products for children with adrenocortical insufficiency, a shortage of hormones from the adrenal glands. GALZIN is a maintenance treatment for Wilson disease, in which the body holds too much copper. It sells ALKINDI SPRINKLE with a sales force aimed at pediatric endocrinologists.

Eton says it competes with other biotechnology and pharmaceutical companies.

Its biggest risks, as it describes them

  • US drug pricing and Medicare rules may cut the prices it gets and demand for its products.
  • Government price reporting and discount programs add complex duties that can lower its net prices.
  • Insurer coverage and cost controls may limit what it can charge.
  • It depends on its approved products and new candidates for revenue.
  • Its focus on rare diseases means small patient groups.
From Eton Pharmaceuticals's annual report on Form 10-K, filed March 19, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Eton Pharmaceuticals lost money in fiscal 2025: a net loss of $5 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1416211526
Debt incl. finance leases5503031
Net debt (negative means net cash)−9−11−21155
Net debt to EBITDA————1.4x
Debt to equity0.3x0.4x0.0x1.2x1.2x
Interest coverage−1.4x−8.7x−1.1x−1.3x−0.2x
Current ratio5.2x3.1x1.6x2.1x1.6x
Quick ratio5.1x3.0x1.6x1.3x1.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Eton Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Eton Pharmaceuticals says to expect

  • Full year 2026: revenue and Adjusted EBITDA marginThe Company now expects 2026 revenue of more than $175 million, an increase from its previous guidance of more than $145 million. The Company also expects at least a 40% Adjusted EBITDA margin for 2026, up from its previous guidance of at least 35%.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Eton Pharmaceuticals shares on the open market, and 5 insiders sold $25.2 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 28, 2026Paul Maier VDirectorSold50,000$59.07$3.0 millionForm 4
Aug 24, 2026David KrempaChief Business OfficerSold25,000$65.07$1.6 millionForm 4
Aug 20, 2026Sean BrynjelsenPresident & CEO, DirectorSold91,022$60.70$5.5 millionForm 4
Aug 19, 2026Sean BrynjelsenPresident & CEO, DirectorSold8,978$62.65$562,472Form 4
Jul 14, 2026Opaleye Management Inc.10% ownerSold28,315$37.54$1.1 millionForm 4
Jul 7, 2026Opaleye Management Inc.10% ownerSold26,685$38.37$1.0 millionForm 4
Jul 6, 2026Opaleye Management Inc.10% ownerSold10,000$38.00$380,000Form 4
Jul 2, 2026Opaleye Management Inc.10% ownerSold90,000$37.39$3.4 millionForm 4
Jun 17, 2026Jennifer McKie AdamsDirectorSold50,000$32.48$1.6 millionForm 4
May 28, 2026Sean BrynjelsenPresident & CEO, DirectorSold120,000$31.88$3.8 millionForm 4
May 27, 2026David KrempaChief Business OfficerSold19,679$31.47$619,298Form 4
May 26, 2026David KrempaChief Business OfficerSold37,524$31.49$1.2 millionForm 4
The latest 12 of 13 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score5 of 93 of 94 of 9
Rule of 4070.4%25.7%117.7%
Altman Z''−7.75−2.54−2.05
Accruals ratio−27.3%−8.9%−18.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positivePassPassPass
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassFailPass
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin roseFailFailFail
Revenue rose relative to assetsPassFailFail
F-score5 of 93 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Eton Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Eton PharmaceuticalsFY25104.9%−1.1%12.8%−1.9%1.4x4
Nurix TherapeuticsFY2554.0%−340.2%−313.7%———Compare
Viridian TherapeuticsFY2523,359.9%−512.9%−390.8%———Compare
Kura OncologyFY2525.2%−449.9%−104.8%——3Compare
Nuvation BioFY25699.0%−338.7%−288.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—102221323980
Revenue growth——−95.9%55,879.5%−2.7%48.9%23.3%104.9%
Gross profit—0−01914212343
Research and development6121464338
Operating income−10−19−27−2−8−1−3−1
Net income−13−18−28−2−9−1−4−5
Diluted EPS (US$)−5.80−1.03−1.33−0.08————
Diluted shares (millions)618212525262627
Cash flow
Cash from operations−8−18−22−557110
Capital expenditure01000000
Free cash flow−8−19−22−557110
Dividends paid00000000
Share buybacks00000000
Acquisitions000000300
Stock-based compensation22334336
Balance sheet at fiscal year end
Cash and short-term investments2712211416211526
Debt incl. finance leases—465503031
Total assets2817262825327692
Total liabilities26111012165266
Shareholders' equity2610181813162426
Margins and ratios
Gross margin—52.8%−1,018.0%87.0%67.4%66.6%60.0%53.5%
Operating margin—−1,939.6%−69,515.4%−6.8%−38.9%−3.8%−6.7%−1.1%
Net margin—−1,910.3%−71,717.9%−8.9%−42.5%−3.0%−9.8%−5.8%
Free cash flow margin—−1,994.0%−57,425.6%−21.7%22.5%21.5%2.4%12.8%
Rule of 40 (growth + FCF margin)——−57,521.6%55,857.8%19.9%70.4%25.7%117.7%
Return on capital——−727.1%−20.8%−122.6%—−12.3%−1.9%
Return on equity—−99.4%−198.5%−11.1%−58.8%−6.6%−19.2%−18.2%
Return on assets—−80.7%−128.9%−7.3%−34.4%−3.3%−7.1%−5.5%
Net debt to EBITDA———————1.4x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Eton Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Eton Pharmaceuticals.